Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tipranavir
Drug: Ritonavir
Drug: Efavirenz

First Posted Date: 2014-08-27

Last Posted Date: 2014-08-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02226991

Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects

Phase 1

Completed

Conditions: HIV/AIDS

Interventions: Drug: Moxifloxacin
Drug: Placebo
Drug: Efavirenz

First Posted Date: 2014-06-17

Last Posted Date: 2015-09-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 58

Registration Number: NCT02164812

Locations: 🇺🇸
Parexel International - Baltimore Epcu, Baltimore, Maryland, United States

Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Drug: Efavirenz
Drug: Raltegravir

First Posted Date: 2013-11-21

Last Posted Date: 2019-02-25

Lead Sponsor: Taipei Veterans General Hospital, Taiwan

Target Recruit Count: 107

Registration Number: NCT01989910

Locations: 🇨🇳
Division of Infectious Diseases, Taipei Veterans General Hospital, Taipei, Taiwan

Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz

Phase 4

Terminated

Conditions: Drug Interaction

Interventions: Drug: Efavirenz

First Posted Date: 2013-11-08

Last Posted Date: 2018-05-11

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 1

Registration Number: NCT01980342

Locations: 🇺🇸
Johns Hopkins University Bayview Medical Center, Baltimore, Maryland, United States

LAAM-HAART PET Imaging

Early Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Radiation: [11c] LAAM
Drug: Ritonavir
Drug: Efavirenz

First Posted Date: 2013-09-05

Last Posted Date: 2017-12-13

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 10

Registration Number: NCT01935830

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection

Phase 4

Completed

Conditions: HCV Coinfection
HIV Infection

Interventions: Drug: Raltegravir
Drug: Efavirenz

First Posted Date: 2013-07-16

Last Posted Date: 2017-07-25

Lead Sponsor: Juan Macías

Target Recruit Count: 45

Registration Number: NCT01900015

Locations: 🇪🇸
H.U. Valme, Seville, Spain
🇪🇸
Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇪🇸
Hospital La Línea, La Línea de la Concepción, Cádiz, Spain

and more 7 locations

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

Completed

Conditions: HIV Infection

Interventions: Drug: Efavirenz

First Posted Date: 2013-06-25

Last Posted Date: 2023-12-12

Lead Sponsor: University of Nebraska

Target Recruit Count: 30

Registration Number: NCT01886404

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB

Phase 3

Completed

Conditions: HIV/TB Co-infection

Interventions: Drug: Nevirapine
Drug: Efavirenz

First Posted Date: 2013-03-06

Last Posted Date: 2013-03-26

Lead Sponsor: All India Institute of Medical Sciences, New Delhi

Target Recruit Count: 135

Registration Number: NCT01805258

Locations: 🇮🇳
All India Institute of Medical Sciences, New Delhi, India

A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

Phase 2

Completed

Conditions: HIV
Contraception

Interventions: Drug: Levonorgestrel
Drug: Nevirapine
Drug: Efavirenz

First Posted Date: 2013-02-12

Last Posted Date: 2023-09-01

Lead Sponsor: University of Nebraska

Target Recruit Count: 60

Registration Number: NCT01789879

Locations: 🇺🇬
Infectious Diseases Institute, Kampala, Uganda

Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine

Phase 4

Completed

Conditions: HIV

Interventions: Drug: ATRIPLA

First Posted Date: 2013-01-29

Last Posted Date: 2015-09-02

Lead Sponsor: Anna Cruceta

Target Recruit Count: 60

Registration Number: NCT01778413

Locations: 🇪🇸
Hospital Clinic i Provincial Barcelona, Barcelona, Spain

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy